-DOCSTART- -X- O
OBJECTIVES -X- _ O
: -X- _ O
To -X- _ O
determine -X- _ O
the -X- _ O
frequency -X- _ B-Intervention
and -X- _ I-Intervention
types -X- _ I-Intervention
of -X- _ I-Intervention
respiratory -X- _ I-Intervention
viruses -X- _ I-Intervention
circulating -X- _ O
in -X- _ O
Boston -X- _ B-Patient
long-term -X- _ I-Patient
care -X- _ I-Patient
facilities -X- _ I-Patient
( -X- _ I-Patient
LTCFs -X- _ I-Patient
) -X- _ I-Patient
during -X- _ O
a -X- _ O
3-year -X- _ O
period. -X- _ O
DESIGN -X- _ O
: -X- _ O
Observational. -X- _ O
SETTING -X- _ O
: -X- _ O
Thirty- -X- _ B-Patient
three -X- _ I-Patient
Boston-area -X- _ I-Patient
LTCFs -X- _ I-Patient
over -X- _ O
a -X- _ O
3-year -X- _ O
period. -X- _ O
PARTICIPANTS -X- _ O
: -X- _ O
Residents -X- _ B-Patient
of -X- _ I-Patient
long-term -X- _ I-Patient
care -X- _ I-Patient
who -X- _ O
had -X- _ O
previously -X- _ O
participated -X- _ O
in -X- _ O
a -X- _ O
trial -X- _ O
of -X- _ O
vitamin -X- _ O
E -X- _ O
supplementation -X- _ O
and -X- _ O
had -X- _ O
paired -X- _ O
serum -X- _ O
samples -X- _ O
available -X- _ O
for -X- _ O
viral -X- _ O
analysis. -X- _ O
MEASUREMENTS -X- _ O
: -X- _ O
Viral -X- _ B-Intervention
antibody -X- _ I-Intervention
titers -X- _ I-Intervention
to -X- _ I-Intervention
eight -X- _ I-Intervention
respiratory -X- _ I-Intervention
viruses -X- _ I-Intervention
( -X- _ I-Intervention
influenza -X- _ I-Intervention
A -X- _ I-Intervention
and -X- _ I-Intervention
B -X- _ I-Intervention
, -X- _ I-Intervention
respiratory -X- _ I-Intervention
syncytial -X- _ I-Intervention
virus -X- _ I-Intervention
( -X- _ I-Intervention
RSV -X- _ I-Intervention
) -X- _ I-Intervention
, -X- _ I-Intervention
parainfluenza -X- _ I-Intervention
virus -X- _ I-Intervention
serotype -X- _ I-Intervention
three -X- _ I-Intervention
( -X- _ I-Intervention
PIV-3 -X- _ I-Intervention
) -X- _ I-Intervention
, -X- _ I-Intervention
PIV-2 -X- _ I-Intervention
, -X- _ I-Intervention
human -X- _ I-Intervention
metapneumovirus -X- _ I-Intervention
( -X- _ I-Intervention
hMPV -X- _ I-Intervention
) -X- _ I-Intervention
, -X- _ I-Intervention
and -X- _ I-Intervention
coronaviruses -X- _ I-Intervention
229E -X- _ I-Intervention
and -X- _ I-Intervention
OC43 -X- _ I-Intervention
) -X- _ I-Intervention
were -X- _ O
measured -X- _ O
using -X- _ O
enzyme -X- _ O
immunoassay -X- _ O
at -X- _ O
baseline -X- _ O
and -X- _ O
53 -X- _ O
weeks. -X- _ O
Infection -X- _ O
was -X- _ O
defined -X- _ O
as -X- _ O
a -X- _ O
more -X- _ O
than -X- _ O
quadrupling -X- _ O
of -X- _ O
viral -X- _ O
titers. -X- _ O
Clinical -X- _ O
data -X- _ O
on -X- _ O
respiratory -X- _ O
illnesses -X- _ O
were -X- _ O
collected -X- _ O
throughout -X- _ O
the -X- _ O
study -X- _ O
period. -X- _ O
RESULTS -X- _ O
: -X- _ O
A -X- _ O
total -X- _ O
of -X- _ O
617 -X- _ O
persons -X- _ O
were -X- _ O
enrolled -X- _ O
in -X- _ O
the -X- _ O
trial. -X- _ O
Of -X- _ O
these -X- _ O
, -X- _ O
382 -X- _ O
( -X- _ O
62 -X- _ O
% -X- _ O
) -X- _ O
had -X- _ O
sera -X- _ O
available -X- _ O
for -X- _ O
viral -X- _ O
analysis. -X- _ O
A -X- _ O
total -X- _ O
of -X- _ O
204 -X- _ B-Outcome
viral -X- _ I-Outcome
infections -X- _ I-Outcome
were -X- _ I-Outcome
documented -X- _ I-Outcome
in -X- _ I-Outcome
157 -X- _ I-Outcome
subjects. -X- _ I-Outcome
Serological -X- _ O
responses -X- _ O
to -X- _ O
all -X- _ O
eight -X- _ O
viruses -X- _ O
were -X- _ O
documented -X- _ O
, -X- _ O
with -X- _ O
hMPV -X- _ B-Outcome
( -X- _ I-Outcome
12.8 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
and -X- _ I-Outcome
coronavirus -X- _ I-Outcome
229E -X- _ I-Outcome
( -X- _ I-Outcome
10.5 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
being -X- _ I-Outcome
the -X- _ I-Outcome
most -X- _ I-Outcome
common -X- _ I-Outcome
and -X- _ I-Outcome
PIV-2 -X- _ I-Outcome
( -X- _ I-Outcome
2.4 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
the -X- _ I-Outcome
least -X- _ I-Outcome
common. -X- _ I-Outcome
The -X- _ O
occurrence -X- _ B-Outcome
of -X- _ I-Outcome
bronchitis -X- _ I-Outcome
( -X- _ I-Outcome
P -X- _ I-Outcome
= -X- _ I-Outcome
.007 -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
pneumonia -X- _ I-Outcome
( -X- _ I-Outcome
P -X- _ I-Outcome
= -X- _ I-Outcome
.02 -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
any -X- _ I-Outcome
lower -X- _ I-Outcome
respiratory -X- _ I-Outcome
tract -X- _ I-Outcome
infection -X- _ I-Outcome
( -X- _ I-Outcome
P -X- _ I-Outcome
= -X- _ I-Outcome
.002 -X- _ I-Outcome
) -X- _ I-Outcome
was -X- _ I-Outcome
significantly -X- _ I-Outcome
associated -X- _ I-Outcome
with -X- _ I-Outcome
having -X- _ I-Outcome
a -X- _ I-Outcome
viral -X- _ I-Outcome
diagnosis. -X- _ I-Outcome
CONCLUSION -X- _ O
: -X- _ O
A -X- _ O
wide -X- _ O
range -X- _ O
of -X- _ O
respiratory -X- _ O
viruses -X- _ O
cocirculates -X- _ O
in -X- _ O
LTCFs -X- _ O
and -X- _ O
contributes -X- _ O
to -X- _ O
respiratory -X- _ O
illness -X- _ O
morbidity -X- _ O
in -X- _ O
these -X- _ O
populations -X- _ O
. -X- _ O

